Kura Oncology, Inc. (KURA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 11 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Tue, Nov 10, 2026after close 41 8-K
Q2 FY2026Wed, Aug 12, 2026after close 43 8-K
Q1 FY2026Tue, May 12, 2026after close 42 8-K
Q4 FY2025Thu, Mar 5, 2026before open 64 8-K
Q3 FY2025Tue, Nov 4, 2025before open 35 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Thu, May 1, 2025after close 31 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML – – FDA alignment for approximately 40-patient monotherapy registrational s" exhibit
Q3 FY2026 "Ziftomenib Development Milestones o Initial topline results from the frontline KOMET-017 registrational program are anticipated in 2028, representing a key milestone in evaluating the potential to expand ziftomenib into newly diagnosed AML. o Eight ziftomenib abstracts will be presented at the 2026 American Society of Hematology (ASH) Annual Meeting, including: – FLT3 inhibitor combinations: Two oral presentations will report encouraging preliminary results for ziftomenib plus quizartinib and 7+3 intensive chemotherapy in newly diagnosed NPM1 -m/ FLT3 -ITD+ AML (KOMET-007) and ziftomenib plus" exhibit
Q3 FY2026 "Kura has updated its 2026 collaboration revenue guidance to $40 million to $45 million for 2026 and is maintaining guidance of $90 million to $110 million in each of 2027 and 2028." exhibit
Q2 FY2026 "Combined with $180 million in anticipated collaboration payments from Kyowa Kirin, the Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KURA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KURA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

KURA earnings date badge

HTML

<a href="https://veritasdata.dev/company/KURA/"><img src="https://veritasdata.dev/embed/KURA.svg" alt="KURA earnings date" width="240" height="56"></a>

Markdown

[![KURA earnings date](https://veritasdata.dev/embed/KURA.svg)](https://veritasdata.dev/company/KURA/)

Script

<script async src="https://veritasdata.dev/embed/KURA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KURA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.